IP Library Granted Patent US 10,391,096
Granted Patent B2
US 10,391,096 · App. 13/272,508 · Granted Aug 27, 2019

Method for treating thrombotic disorders using quercetin-containing compositions

Inventor: Thomas Christian Lines (Wayland, MA)
Assignee: Quercegen Pharmaceuticals LLC
A61K31/519A61K31/352A61K31/375A61K31/4365A61K31/455A61K31/7048A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,391,096
App. No.
13/272,508
Granted
Aug 27, 2019
Kind
B2
Abstract

A method for treating thrombotic disorders using a composition containing quercetin, together with one or more of vitamin B 3 , vitamin C, and folic acid. Also disclosed is a method of improving the efficacy of a blood thinning medication by co-administering a composition containing quercetin, together with one or more of vitamin B 3 , vitamin C, and folic acid to a subject being treated with a blood thinning medication.

Claims (10)

1. A method for treating a thrombotic disorder, the method comprising administering to a subject in need thereof an effective amount of a composition that includes isoquercetin, vitamin B3, vitamin C, and folic acid, wherein the thrombotic disorder is venous thrombosis.

2. The method of claim 1 , further comprising administering an anticoagulant.

3. The method of claim 1 , wherein the venous thrombosis is deep vein thrombosis or pulmonary embolism; is associated with factor V Leiden, antithrombin III deficiency, protein C deficiency, protein S deficiency, prothrombin gene mutation (G20210A), thrombosis syndrome, major surgery, immobilization, oral contraceptive use, thalidomide use, pregnancy, myeloproliferative disorders, nephrotic syndrome, paroxysmal nocturnal hemoglobinuria, or trauma; or is induced by cancer.

4. The method of claim 2 , wherein the anticoagulant is acenocoumarol, coumatetralyl, dicoumarol, ethyl biscoumacetate, phenprocoumon, clorindione, diphenadione, phenindione, tioclomarol, bemiparin, certoparin, dalteparin, nadroparin, parnaparin, reviparin, tinzaparin, fondaparinux, idraparinux, danaparoid, sulodexide, dermatan sulfate, apixaban, betrixaban, edoxaban, otamixaban, rivaroxaban, bivalirudin, lepirudin, desirudin, argatroban, dabigatran, melagatran, ximelagatran, regimen 1, defibrotide, ramatroban, antithrombin III, or drotrecogin alfa.

5. The method of claim 1 , wherein the venous thrombosis is induced by cancer.

6. The method of claim 1 , wherein the composition includes about 250 mg to about 1000 mg of isoquercetin.

7. The method of claim 1 , wherein the composition includes about 20 μg to about 3 g of Vitamin B3.

8. The method of claim 1 , wherein the composition includes about 200 μg to about 3 g of Vitamin C.

9. The method of claim 1 , wherein the composition includes about 1000 μg to about 3000 μg of folic acid.

10. The method of claim 1 , wherein the effective amount is sufficient to reduce the level of protein disulfide isomerase activity in the serum of the subject.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2020
From: QUERCEGEN PHARMA A.G.
To: LINES, THOMAS CHRISTIAN
Reel/Frame 052151/0234 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2020
From: LINES, THOMAS CHRISTIAN
To: QUERCIS PHARMA A.G.
Reel/Frame 052153/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2020
From: LINES, THOMAS; QUERCEGEN PHARMA LLC; QUERCEGEN PHARMA LLP; QUERCEGEN TECHNOLOGIES; QUERCEGEN PHARMACEUTICALS, LLC; QUERCEGEN HOLDINGS, LLC; NEW SUN NUTRITION, LLC; THE FRS COMPANY
To: QUERCEGEN PHARMA, AG.
Reel/Frame 052110/0530 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2012
From: LINES, THOMAS CHRISTIAN
To: QUERCEGEN PHARMACEUTICALS LLC
Reel/Frame 028967/0088 →
Continuity (1)
Related Publication 20130095095A1 · Apr 18, 2013
Cited By (3)
US 12,290,527 US 12,403,122 US 12,403,123